Shots:

• Takeda will provide upfront of $30M and to pay royalties on commercialization. CD38-Targeted ETBs' development cost will be shared equally between both the parties
• Molecular Templates will receive development- regulatory and commercial milestone payments of up to $632.5M if company exercise its co-development option- or $337.5M if it does not exercise or opts out of its co-development option
• In Oct 2016- Takeda and Molecular signed agreement to develop CD38-targeted ETBs for oncology drug discovery programs

 Ref: Molecular Templates | Image: Takeda